Nasdaq ardx.

Ardelyx, Inc.'s (NASDAQ:ARDX) top owners are individual investors with 53% stake, while20% is held by institutions. Read full article. Simply Wall St. November 8, 2022 at 5:48 AM ...

Nasdaq ardx. Things To Know About Nasdaq ardx.

WALTHAM, Mass., Nov. 21, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class ...WALTHAM, Mass., Nov. 06, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class ...Ardelyx Stock (NASDAQ:ARDX), Short Interest Report. Short interest for Ardelyx gives investors a sense of the degree to which investors are betting on the decline of Ardelyx's stock.Shares of Ardelyx ( ARDX 3.20%) were down more than 12% as of 3:30 p.m. on Wednesday. The healthcare company, which has a chronic kidney disease (CKD) drug that is awaiting approval later this ...

Ardelyx (NASDAQ: ARDX) stock is climbing today after the U.S. Food and Drug Administration ( FDA) approved the firm’s treatment for excessive phosphate levels in kidney disease patients. Shares ...

From discovery through commercialization, all of us at Ardelyx ® are driven to advance patient care with targeted, first-in-class, novel mechanism therapies that address significant unmet medical needs. We developed a unique and innovative platform that enabled the discovery of new biological mechanisms and pathways to create targeted, first ...

Ardelyx (NASDAQ:ARDX – Get Free Report)‘s stock had its “outperform” rating reiterated by investment analysts at Wedbush in a report released on Friday, Benzinga reports. They currently have a $9.00 price objective on the biopharmaceutical company’s stock. Wedbush’s price objective would suggest a potential upside of 89.08% from the company’s previous close. Several other ...WALTHAM, Mass., Sept. 28, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in ...May 5, 2023 · Ardelyx Inc. (NASDAQ:ARDX) is a biopharmaceutical company based in Waltham, Massachusetts. The company develops and commercialized medicines to treat gastrointestinal and cardiorenal therapeutic ... WALTHAM, Mass., Oct. 17, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class ...WALTHAM, Mass., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class ...

Nov 16, 2023 · Ardelyx Inc (NASDAQ:ARDX) showed a performance of -1.41% in past 30-days. Number of shares sold short was 36.47 million shares which calculate 4.09 days to cover the short interests. Wall Street analysts have assigned a consensus price target of $9.64 to the stock, which implies a rise of 59.96% to its recent value today.

Ardelyx Inc (NASDAQ:ARDX)’s Major holders. Ardelyx Inc insiders own 1.74% of total outstanding shares while institutional holders control 56.10%, with the float percentage being 57.09%. State Street Corporation is the largest shareholder of the company, while 176 institutions own stock in it. As of Jun 29, 2023, the company held …

FREMONT, Calif. and WALTHAM, Mass., July 29, 2021 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company focused on the discovery, development, and commercialization of innovative first-in-class medicines to improve treatment for people with kidney and cardiorenal diseases, today announced that it has …Nasdaq 14,305.03 +78.81(+0.55%) Russell 2000 1,862.64 +53.62(+2.96%) Crude Oil 74.38 -1.58(-2.08%) Gold 2,091.70 +34.50(+1.68%) Advertisement Ardelyx, Inc. (ARDX) …Ardelyx (NASDAQ: ARDX), a biotech innovator, is arguably one of the best picks among penny stocks to buy.Its powerful portfolio, featuring IBSRELA for IBS-C and XPHOZAH for chronic kidney disease ...WALTHAM, Mass., March 02, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in ...Ardelyx (NASDAQ:ARDX) is scheduled to announce Q4 earnings results on Thursday, March 2nd, after market close.The consensus EPS Estimate is -$0.02 and the consensus Revenue Estimate is $23.18M (vs ...Aug 31, 2023 · Fintel reports that on September 12, 2023, HC Wainwright & Co. reiterated coverage of Ardelyx (NASDAQ:ARDX) with a Buy recommendation. Analyst Price Forecast Suggests 77.74% Upside. As of August ... Find the latest Institutional Holdings data for Ardelyx, Inc. Common Stock (ARDX) at Nasdaq.com.

Ardelyx (NASDAQ: ARDX) is a biotechnology company that focuses on developing novel therapies for unmet medical needs. The company’s growth and potential breakthroughs in medical treatments could ...From discovery through commercialization, all of us at Ardelyx ® are driven to advance patient care with targeted, first-in-class, novel mechanism therapies that address significant unmet medical needs. We developed a unique and innovative platform that enabled the discovery of new biological mechanisms and pathways to create targeted, first ... 3 Penny Stocks to Buy and Hold for the Next 10 Years. 1 month ago. Simply Wall St. 1 week ago. Ardelyx (NASDAQ:ARDX) delivers shareholders splendid 109% return over 1 year, …11 thg 8, 2020 ... Ardelyx, Inc. filed an NDA for its chief asset tenapanor in the control of serum phosphorus in adults with chronic kidney disease on ...Ardelyx (NASDAQ: ARDX), a biotech innovator, is arguably one of the best picks among penny stocks to buy.Its powerful portfolio, featuring IBSRELA for IBS-C and XPHOZAH for chronic kidney disease ...

Ardelyx, Inc. Common Stock (ARDX). Nasdaq Listed ...

Ardelyx (NASDAQ: ARDX) is a biotechnology company that focuses on developing novel therapies for unmet medical needs. The company’s growth and potential breakthroughs in medical treatments could ...From discovery through commercialization, all of us at Ardelyx ® are driven to advance patient care with targeted, first-in-class, novel mechanism therapies that address significant unmet medical needs. We developed a unique and innovative platform that enabled the discovery of new biological mechanisms and pathways to create targeted, first ... WALTHAM, Mass., Oct. 17, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class ...WALTHAM, Mass., Oct. 17, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class ...Ardelyx Stock (NASDAQ:ARDX), Short Interest Report. Short interest for Ardelyx gives investors a sense of the degree to which investors are betting on the decline of Ardelyx's stock. WALTHAM, Mass., Oct. 04, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class ...Ardelyx (ARDX) Reports Q1 Loss, Tops Revenue Estimates Zacks - Wed May 3, 4:15PM CDT . Ardelyx (ARDX) delivered earnings and revenue surprises of -18.18% and 12.83%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?Ardelyx, Inc. Common Stock (ARDX) Real-time Stock Quotes - Nasdaq offers real-time quotes & market activity data for US and global markets. S hares of Ardelyx ( NASDAQ: ARDX) were down 17% in afternoon trading Wednesday ahead of an expected FDA decision on its kidney disease treatment candidate Xphozah and amid a market-moving update ...

WALTHAM, Mass., Oct. 18, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class ...

We are committed to serving the best interests of our shareholders. You will find key shareholder information and financial reports available to help put Ardelyx’s financial performance into perspective. NASDAQ: ARDX. $4.76. …

Q1 net loss was $26.8 million, but Ardelyx raised $51.9 million through sales of their common stock at an average price of about $3.35, leaving $130.4 million in total cash and investments as of ...Dec 1, 2023 · Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company’s lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation. Ardelyx, Inc. (NASDAQ:ARDX) is a Waltham, Massachusetts-based biopharmaceutical company focused on the development of first-in-class remedies that meet significant unmet medical needs.Ardelyx Inc. (NASDAQ:ARDX) is a biopharmaceutical company based in Waltham, Massachusetts. The company develops and commercialized medicines to treat gastrointestinal and cardiorenal therapeutic ...Ardelyx, Inc. Common Stock (ARDX) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets.Ardelyx (ARDX) Reports Q1 Loss, Tops Revenue Estimates Zacks - Wed May 3, 4:15PM CDT . Ardelyx (ARDX) delivered earnings and revenue surprises of -18.18% and 12.83%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?WALTHAM, Mass., Sept. 11, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in ...WALTHAM, Mass., Oct. 20, 2022 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative first-in-class ...WALTHAM, Mass., May 15, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class ...WALTHAM, Mass., Nov. 21, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class ...

WALTHAM, Mass., Dec. 29, 2022 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative first-in-class medicines that meet significant unmet medical needs, today announced that the Office of New Drugs (OND), Center for Drug Evaluation and Research of the U ...Find the latest Insider Activity data for Ardelyx, Inc. Common Stock (ARDX) at Nasdaq.com.Ardelyx (NASDAQ:ARDX) is a good speculative biotech to look into. That's because it has been able to generate a good amount of sales with its drug ibsrela for the treatment of adults with ...ARDX Stock 12 Months Forecast. $9.92. (177.48% Upside) Based on 7 Wall Street analysts offering 12 month price targets for Ardelyx in the last 3 months. The average price target is $9.92 with a high forecast of $12.00 and a low forecast of $7.00. The average price target represents a 177.48% change from the last price of $3.58. Instagram:https://instagram. gun and trophy insuranceforex.com appis land a good investment right nowm and t first time home buyer Ardelyx, Inc. (NASDAQ:ARDX) issued its earnings results on Tuesday, October, 31st. The biopharmaceutical company reported $0.03 EPS for the quarter, topping analysts' consensus estimates of ($0.11) by $0.14. The biopharmaceutical company earned $56.39 million during the quarter, compared to analysts' expectations of $22.09 million. funded trader programphlx semiconductor index WALTHAM, Mass., March 02, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today reported financial results for the fourth quarter and full year ended … dividends amazon WALTHAM, Mass., May 17, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class ...Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that the U.S. Food and Drug Administration (FDA) has accepted its resubmission of a New Drug Application (NDA) for XPHOZAH® (tenapanor) for the control of serum phosphate in adult ...